ALP.Lab and Cepton Deploy Lidar Intelligence to Enable Smart Intersections and Road Safety in Europe
Cepton, a leading provider of intelligent, lidar-based solutions, and the Austrian Industry and Testing Alliance ALP.Lab have partnered to build lidar-equipped testing environments for studying complicated road driving situations. For the first time in Austria, this project will deliver real-world traffic data from complex urban and rural alpine intersections.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005304/en/
ALP.Lab has deployed Cepton’s Helius™ Smart Lidar System to capture real-time, 3D traffic data to support the training of AI algorithms used for the scenario-based testing of ADAS and AV features. Courtesy of ALP.Lab.
As an alliance of automotive suppliers such as Magna and AVL, and as a partner to scientific organizations like Virtual Vehicle Research, Joanneum Research and Graz University of Technology, ALP.Lab delivers real-life data on complex traffic situations to test the capabilities of the autonomous driving systems, and helps enable solutions to reduce accidents and improve traffic flows.
From narrow, foggy streets covered in snow, to cyclists overtaking a tram in the middle of an intersection, Austria, with its mountainous landscape, sees varied road driving scenarios and faces unique challenges in ensuring vehicle and pedestrian safety. Difficult traffic scenarios could pose obstacles for the seamless deployment of autonomous mobility solutions. Compiling a realistic database of different driving scenarios is, therefore, pivotal to the testing and verification of advanced driver assistance systems (ADAS) and autonomous vehicles (AVs), to ensure that they work well in complex environments.
Through this new partnership, ALP.Lab has deployed Cepton’s Helius™ Smart Lidar System to capture real-time, 3D traffic data to support the training of artificial intelligence (AI) algorithms used for the scenario-based testing of ADAS and AV features. Additionally, the collected data will make it possible to predict vehicle trajectories at intersections and enable traffic data analysis for traffic flow optimization.
As part of the Helius system, a number of Vista®-P60 lidar sensors from Cepton have been installed at the corners of road intersections and traffic roundabouts, complementing other sensor types including radar and other types of optical sensors. For traffic monitoring and analysis applications, lidars perform well in many critical cases where other sensor types struggle. Lidars offer 24/7 availability thanks to their superior perception capabilities in various lighting conditions, such as night-time, shadows and the glare of strong headlights. Lidars also offer much higher angular resolution compared to radars and minimize false negatives and false positives. The Vista-P60 lidars, powered by Cepton’s patented Micro Motion Technology (MMT®), offer a high detection range of 200 m at 30% reflectivity and an angular resolution of 0.25°, making it possible to accurately detect each arriving and departing vehicle and pedestrian at a distance of up to ~170 meters around the intersections.
The advanced Helius perception software adds an additional layer of intelligence to the lidar data from the Vista-P60. Helius takes the point cloud data from a connected network of Vista-P60 sensors and delivers real-time, 3D information on object dimensions, locations and velocities. This enables Helius to accurately track and classify the different objects involved in a traffic situation. As Helius and the other sensors used by ALP.Lab only capture anonymized data, it protects the privacy of pedestrians and vehicles while feeding ALP.Lab rich traffic data for deeper analysis.
The Helius Smart Lidar system offers optimal ease of integration. The rotation-free, mirrorless and frictionless design makes Vista-P60 sensors very durable and embeddable. The rugged sensor housing is designed to withstand harsh outdoor environments and cold climates, resulting in product robustness and longevity to drive down maintenance costs. With the pre-installed Helius software running on an edge computer, which connects a scalable network of lidar sensors, Helius is a truly plug-and-play system that is extremely easy to set up and scale up.
“We primarily selected Cepton's lidar solutions because of their durability and precise detection capabilities even at high vehicle speeds. With the information the lidar sensors provide, our data is as close to real-life as it gets. Therefore, we are able to create enhanced simulation and AV testing environments as well as detailed analyses of the traffic flow,” said Christian Schwarzl, Director of Testing and Validation from ALP.Lab. “There is amazing synergy between Cepton and ALP.Lab, as we share the same goal of making ADAS and AV features available to the mass market and to improve the safety of vulnerable road users.”
“Lidar plays a crucial role in the future of autonomous mobility, by not only serving as the 'eyes' of vehicles but also bringing intelligence to the traffic infrastructure supporting safe autonomy. In order to make ADAS and AV capabilities available to the broader public, it is crucial to gather information on traffic scenarios that all vehicles are likely to be confronted with, in order to generate proper testing environments and ensure safer roads,” said Dr. Jun Pei, CEO of Cepton. “So, we are excited to partner with ALP.Lab in this endeavor, and we are gratified that our technology can contribute significantly to its success.”
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn.
About ALP.Lab
ALP.Lab is the Austrian Light Vehicle Proving Region for Automated Driving and provides comprehensive services for safe and secure testing of automated driving technologies.
Founded in 2017, ALP.Lab provides an integrated test chain for automated driving functions and vehicles, enabling testing activities in both the virtual and real world. ALP.Lab offers a holistic traffic monitoring solution to create testing scenarios out of real-life driving behavior in primary, secondary, and urban road networks. Further, ALP.Lab provides a professional testing team for Euro-NCAP-compliant ADAS/AD testing, including extensive testing equipment and different proving grounds. A unique mobile HIL (hardware-in-the-loop) system facilitates complex sensor testing and validation.
A strong network of industrial and scientific partners support the capabilities of ALP.Lab for safe and secure testing of any autonomous mobility solutions. Creating value for their customers by providing high-end testing facilities and real-time traffic data is the main driver for the Austrian Light Vehicle Proving Region for Automated Driving.
For more information, visit www.alp-lab.at and follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005304/en/
Contact information
Faithy Li, Cepton Technologies, media@cepton.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
